CORES: An automated method for generating three-dimensional models of protein/ligand complexes

被引:35
作者
Hare, BJ [1 ]
Walters, WP [1 ]
Caron, PR [1 ]
Bemis, GW [1 ]
机构
[1] Vertex Pharmaceut, Cambridge, MA 02139 USA
关键词
D O I
10.1021/jm0499054
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We describe a new, automated method for building 3D models of small-molecule ligands complexed with proteins. Modeling templates are constructed from frameworks (i.e., ring systems and linkers) of ligands extracted from 3D structures of ligands complexed with proteins that are structurally related to the target protein. These templates are typically substructures of the target ligand and are used to build models that constrain the ligand's conformation and binding orientation in the active site of the target protein. The practical utility of the method is shown by demonstrating that most ligands containing related frameworks bind protein kinases in the same orientation. Moreover, models for 15 of 19 cdk2/ligand complexes in the protein data bank built using our method deviate from the X-ray structure by less than 2 A (rms). Finally, we show that over 70% of small-molecule protein kinase inhibitors published in J. Med. Chem. since 1993 can be modeled using a template extracted from a 3D protein kinase structure in the protein data bank.
引用
收藏
页码:4731 / 4740
页数:10
相关论文
共 32 条
[1]   Protein structure prediction and structural genomics [J].
Baker, D ;
Sali, A .
SCIENCE, 2001, 294 (5540) :93-96
[2]   Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: Identification and optimisation of substituted 4,6-bis anilino pyrimidines [J].
Beattie, JF ;
Breault, GA ;
Ellston, RPA ;
Green, S ;
Jewsbury, PJ ;
Midgley, CJ ;
Naven, RT ;
Minshull, CA ;
Pauptit, RA ;
Tucker, JA ;
Pease, JE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :2955-2960
[3]   The properties of known drugs .1. Molecular frameworks [J].
Bemis, GW ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2887-2893
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis [J].
Bramson, HN ;
Corona, J ;
Davis, ST ;
Dickerson, SH ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Harris, PA ;
Hassell, A ;
Holmes, WD ;
Hunter, RN ;
Lackey, KE ;
Lovejoy, B ;
Luzzio, MJ ;
Montana, V ;
Rocque, WJ ;
Rusnak, D ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4339-4358
[6]   Molecular recognition and docking algorithms [J].
Brooijmans, N ;
Kuntz, ID .
ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 2003, 32 :335-373
[7]   Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor [J].
Davies, TG ;
Bentley, J ;
Arris, CE ;
Boyle, FT ;
Curtin, NJ ;
Endicott, JA ;
Gibson, AE ;
Golding, BT ;
Griffin, RJ ;
Hardcastle, IR ;
Jewsbury, P ;
Johnson, LN ;
Mesguiche, V ;
Newell, DR ;
Noble, MEM ;
Tucker, JA ;
Wang, L ;
Whitfield, HJ .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (10) :745-749
[8]   Alternative binding modes of an inhibitor to two different kinases [J].
De Moliner, E ;
Brown, NR ;
Johnson, LN .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2003, 270 (15) :3174-3181
[9]   Inhibition of protein kinase CK2 by anthraquinone-related compounds - A structural insight [J].
De Moliner, E ;
Moro, S ;
Sarno, S ;
Zagotto, G ;
Zanotti, G ;
Pinna, LA ;
Battistutta, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1831-1836
[10]   Receptor tyrosine kinases: The main targets for new anticancer therapy [J].
Drevs, J ;
Medinger, M ;
Schmidt-Gersbach, C ;
Weber, R ;
Unger, C .
CURRENT DRUG TARGETS, 2003, 4 (02) :113-121